Adenocarcinoma, Clear Cell
"Adenocarcinoma, Clear Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)
| Descriptor ID |
D018262
|
| MeSH Number(s) |
C04.557.470.200.025.045
|
| Concept/Terms |
Adenocarcinoma, Clear Cell- Adenocarcinoma, Clear Cell
- Adenocarcinomas, Clear Cell
- Clear Cell Adenocarcinoma
- Clear Cell Adenocarcinomas
|
Below are MeSH descriptors whose meaning is more general than "Adenocarcinoma, Clear Cell".
Below are MeSH descriptors whose meaning is more specific than "Adenocarcinoma, Clear Cell".
This graph shows the total number of publications written about "Adenocarcinoma, Clear Cell" by people in this website by year, and whether "Adenocarcinoma, Clear Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 3 | 0 | 3 |
| 2016 | 3 | 0 | 3 |
| 2017 | 3 | 0 | 3 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adenocarcinoma, Clear Cell" by people in Profiles.
-
Glycogen-rich Clear Cell Carcinoma of the Breast: A Comprehensive Review. Appl Immunohistochem Mol Morphol. 2020 10; 28(9):655-660.
-
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol. 2018 08; 150(2):247-252.
-
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 2017 11; 147(2):243-249.
-
Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women. Gynecol Oncol. 2017 08; 146(2):268-272.
-
Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. J Natl Cancer Inst. 2017 03 01; 109(3):1-10.
-
Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol. 2016 Dec; 143(3):460-465.
-
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. Gynecol Oncol. 2016 Dec; 143(3):484-489.
-
Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials. Int J Gynecol Cancer. 2016 May; 26(4):648-54.
-
Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary. Int J Gynecol Cancer. 2016 Jan; 26(1):120-4.
-
Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Cancer. 2016 Feb 15; 122(4):588-597.